Nanobiotix Stock: +886% in One Year, Eyeing the €29.35 Resistance
Nanobiotix drops 0.99% to €28.06 in late afternoon trading on Euronext Paris, amidst a 0.34% decline in the CAC 40. The oncological nanomedicine biotech maintains an impressive 886% performance over twelve months and 54% over three months. The stock is currently trading close to its technical resistance at €29.35.
Measured Consolidation After an Exceptional Rally
Today's decline remains limited following the surge in recent months. Nanobiotix's stock price has nearly tenfold increased over the year, rising from below €3 in April 2025 to over €28 today. Over seven sessions, the stock still gains 6.53%. The session is part of a downward-oriented Parisian market, with the SBF 120 falling by 0.32%. Comparable biotech sector stocks are following a similar path: Argenx is down 2.52% and Abivax 2.93%. Nanobiotix's movement appears more moderate than its European peers. The sectoral context is dominated by energy and geopolitical tensions, unrelated to the defensive profile of clinical biotechs. The beta of 0.25 indeed shows a low correlation with the variations of the Parisian market.
Stock Price Challenges the €29.35 Resistance
Technically, the stock price is at €28.06, very close to the identified resistance at €29.35. The upper limit of the Bollinger Bands is at €29.33, placing the stock in the upper 71% of the band. The RSI at 55 remains in the neutral zone, with no overbought signal. The stock price is significantly above its 50-day moving average (€26.32) and its 200-day average (€17.34), confirming a fundamentally bullish orientation. The gap between the stock price and the 200-day MA exceeds 60%. Regarding news, the company presented new preclinical data on its nanoprimer platform at the AACR congress on April 20. At the end of March, Nanobiotix also communicated on the progress of its clinical program JNJ-1900 (NBTXR3) and the extension of its cash horizon. The €29.35 resistance remains the next technical level to watch.
